5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted deletion of Tmprss2, we demonstrate that the activity of this protease regulates cancer cell invasion and metastasis to distant organs. By screening combinatorial peptide libraries, we identified a spectrum of TMPRSS2 substrates that include pro-hepatocyte growth factor (HGF). HGF activated by TMPRSS2 promoted c-MET receptor tyrosine kinase signaling, and initiated a proinvasive epithelial-to-mesenchymal transition phenotype. Chemical library screens identified a potent bioavailable TMPRSS2 inhibitor that suppressed prostate cancer metastasis in vivo. Together, these findings provide a mechanistic link between androgen-regulated signaling programs and prostate cancer metastasis that operate via context-dependent interactions with extracellular constituents of the tumor microenvironment.

          Related collections

          Author and article information

          Journal
          Cancer Discov
          Cancer discovery
          2159-8290
          2159-8274
          Nov 2014
          : 4
          : 11
          Affiliations
          [1 ] Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
          [2 ] Department of Pathology, University of Washington, Seattle, Washington.
          [3 ] Department of Urology, University of Washington, Seattle, Washington.
          [4 ] Department of Medicine, University of Washington, Seattle, Washington.
          [5 ] Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Medicine, University of Washington, Seattle, Washington.
          [6 ] Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
          [7 ] Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Pathology, University of Washington, Seattle, Washington. Department of Urology, University of Washington, Seattle, Washington. Department of Medicine, University of Washington, Seattle, Washington. pnelson@fhcrc.org.
          Article
          2159-8290.CD-13-1010 NIHMS621411
          10.1158/2159-8290.CD-13-1010
          4409786
          25122198
          b7240db7-3a57-41c4-a93d-4d251b029dba
          ©2014 American Association for Cancer Research.
          History

          Comments

          Comment on this article